Table 1:
Baseline participant characteristics
| Variable | Usual Care (n = 782) | Intervention (n = 681) |
|---|---|---|
| Age, mean (SD), years | 58.0 (14.4) | 58.6 (14.2) |
| Male Sex, % | 82.7 | 80.3 |
| Racea, % | ||
| American Indian / Eskimo | 0.4 | 0.4 |
| Asian | 26.0 | 19.8 |
| Black | 13.9 | 11.3 |
| Hawaiian or Pacific Islander | 4.9 | 4.6 |
| White | 37.9 | 45.2 |
| Unknown | 17.0 | 18.6 |
| Hispanic ethnicity, % | 23.3 | 25.7 |
| Body mass index, mean (SD), kg/m2 | 31.5 (6.5) | 31.5 (7.6) |
| Serum urate, mean (SD), mg/dl | 8.4 (1.6) | 8.4 (1.5) |
| Serum creatinine, mean (SD), mg/day | 1.16 (0.35) | 1.16 (0.35) |
| Allopurinol dose, mean (SD), mg/day | 188 (101) | 190 (98) |
| Allopurinol dose, mg/day, % | ||
| <100 | 0.9 | 0.6 |
| 100 to <200 | 50.1 | 48.9 |
| 200 to <300 | 14.1 | 12.9 |
| 300 | 33.1 | 36.9 |
| >300 | 1.8 | 0.7 |
| Index year of first allopurinol prescriptiona, % | ||
| 2014 | 59.3 | 53.6 |
| 2015 | 40.7 | 46.4 |
| Colchicine useb, % | 53.6 | 55.1 |
| Prescription NSAID useb, % | 49.2 | 51.4 |
| Glucocorticoid useb, % | 37.5 | 36.9 |
| Thiazide diureticb, % | 9.1 | 11.7 |
| Loop diureticb, % | 8.7 | 6.9 |
| Diabetes mellitusb, % | 21.7 | 23.1 |
| Hypertensionb, % | 57.8 | 59.8 |
a
Group differences examined using either chi square test or student‟s t-test; all comparisons were non-significant with the exception of race (p=0.020) and calendar year of first prescription (p=0.027)
b
Comorbidities and drug use defined using administrative diagnostic codes and pharmacy dispending data over the 12-month period preceding the first allopurinol prescription; NSAID = non-steroidal anti-inflammatory drug